$363 Million is the total value of Iguana Healthcare Management, LLC's 133 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RAD | Exit | RITE AID CORP | $0 | – | -150,000 | -100.0% | -0.25% | – |
| Exit | SANOFIcall | $0 | – | -15,000 | -100.0% | -0.41% | – | |
| XNCR | Exit | XENCOR INC | $0 | – | -40,000 | -100.0% | -0.48% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -7,500 | -100.0% | -0.50% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -75,000 | -100.0% | -0.64% | – |
| Exit | IMMUNOMEDICS INCcall | $0 | – | -150,000 | -100.0% | -0.75% | – | |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -15,000 | -100.0% | -0.85% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -20,000 | -100.0% | -1.00% | – |
| Exit | BIOMARIN PHARMACEUTICALcall | $0 | – | -25,000 | -100.0% | -1.28% | – | |
| NUVA | Exit | NUVASIVE INC | $0 | – | -35,000 | -100.0% | -1.52% | – |
| Exit | ALEXION PHARMACEUTICALS INCcall | $0 | – | -25,000 | -100.0% | -1.72% | – | |
| Exit | ASTRAZENECA PLCput | $0 | – | -100,000 | -100.0% | -1.93% | – | |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -75,000 | -100.0% | -2.03% | – |
| Exit | CLOVIS ONCOLOGY INCput | $0 | – | -40,000 | -100.0% | -2.12% | – | |
| SPNC | Exit | SPECTRANETICS CORP | $0 | – | -110,000 | -100.0% | -2.39% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -25,000 | -100.0% | -3.44% | – |
| Exit | MERCK & CO INCcall | $0 | – | -100,000 | -100.0% | -3.62% | – | |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -40,000 | -100.0% | -3.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.